Company Filing History:
Years Active: 2004-2005
Title: Stephanie A. Robertson: Innovator in Genetic Modulation
Introduction
Stephanie A. Robertson is a prominent inventor based in San Francisco, California. She has made significant contributions to the field of genetic modulation, particularly in relation to the p21 pathway and Rhomboid Related Proteins (RRPs). With a total of three patents to her name, her work has the potential to impact therapeutic approaches for various disorders.
Latest Patents
Robertson's latest patents include groundbreaking research on HADHs as modifiers of the p21 pathway. This patent identifies human HADH genes as modulators of the p21 pathway, presenting them as therapeutic targets for disorders associated with defective p21 function. Additionally, she has developed methods for identifying modulators of p21, which involve screening for agents that can modulate the activity of HADH. Another significant patent focuses on human RRP sequences and their methods of use. This research highlights the role of RRPs in the EGFR signaling pathway and includes the development of transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide. These innovations also encompass methods for modulating the interaction of RRP proteins with their pathway members.
Career Highlights
Robertson is currently employed at Exelixis, Inc., where she continues to advance her research in genetic modulation. Her work has garnered attention for its potential applications in cancer treatment, particularly in inhibiting the growth of tumor cells that overexpress RRP proteins.
Collaborations
Some of her notable coworkers include Lori Friedman and Marcia Belvin, who contribute to her research endeavors and collaborative projects.
Conclusion
Stephanie A. Robertson is a leading figure in the field of genetic modulation, with her innovative patents paving the way for new therapeutic strategies. Her contributions to understanding the p21 pathway and RRPs are invaluable to the scientific community.